Whole-exome sequencing from specimens of the initial AML, first complete remission after chemotherapy, the first relapse, donor PBSCs, DCL at 27 and DCL at 36 months revealed that IDH2(R140Q) and DNMT3A(V150Gfs) mutations were present in the healthy donor cells at a low frequency and were potentially responsible for DCL[11]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.